Dublin, July 18, 2023 (GLOBE NEWSWIRE) -- The "Dry Eye Disease - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Dry Eye Disease- Pipeline Insight, 2023" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Dry Eye Disease pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dry Eye Disease pipeline landscape is provided which includes the disease overview and Dry Eye Disease treatment guidelines. The assessment part of the report embraces, in depth Dry Eye Disease commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Eye Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Dry Eye Disease R&D. The therapies under development are focused on novel approaches to treat/improve Dry Eye Disease.
Dry Eye Disease Emerging Drugs Chapters
This segment of the Dry Eye Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dry Eye Disease Emerging Drugs
AR-15512: Alcon
AR-15512 is an investigational eye drop currently in clinical development at Aerie as a potential treatment for the signs and symptoms of dry eye disease. It has not been approved by the US Food and Drug Administration (FDA). The active ingredient in AR-15512 is a proprietary small-molecule selective agonist of the transient receptor potential melastatin 8 (TRPM8) cold thermoreceptor, which represents a novel therapeutic target for dry eye. Currently, the drug is in Phase III stage of its development for the treatment of dry eyes disease.
HL036: HanAll Biopharma
HL036 (tanfanercept), jointly developed by HanAll Biopharma and Daewoong Pharmaceutical, is a novel, topical biologic treatment under development to treat inflammatory eye diseases by inhibiting TNF, which is involved in ocular inflammation. The first Phase III clinical trial (VELOS-2) for dry eye disease was completed in the US. It is being developed in Phase III in China by Harbour BioMed, HanAll's out-licensing partner for the greater China region.
OTX-DED: Ocular Therapeutix
OTX-DED, is a low dose, intracanalicular insert of dexamethasone for the treatment of patients with episodic dry eye disease. OTX-DED is designed to release dexamethasone over a period of two to three weeks for the short-term treatment of the signs and symptoms of dry eye disease. OTX-DED may offer patients the opportunity to be treated with a physician-administered, preservative-free and hands-free steroid therapy. Currently, the drug is in Phase II stage of its development for the treatment of dry eyes disease.
SY-201: Seinda Pharmaceutical
SY-201, which is being developed by Seinda Pharmaceutical, is under developmental Phase I/II for the treatment of dry eye disease. It is administered through ophthalmic route in the form of solution.
iVIEW 1001: IVIEW Therapeutics
IVW-1001 is a TRPM8 receptor agonist which selectively activates TRPM8 receptors and their activation has the potential to reduce discomfort. Evidence from clinical studies showed that topical TRPM8 activation reduced eye discomfort and increased tear secretion in those with DED.
In January 2023, iVIEW Therapeutics announced that the company completed a successful pre-IND meeting with FDA and received the agency's full agreement on all CMC, non-clinical and clinical development plans to develop IVW-1001 for the treatment of sign and symptoms of dry eye disease (DED). The company is targeting to initiate Phase I/II clinical trials for dry eye patients in the end of 2023.
Dry Eye Disease: Therapeutic Assessment
This segment of the report provides insights about the different Dry Eye Disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Dry Eye Disease
There are approx. 45+ key companies which are developing the therapies for Dry Eye Disease. The companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e. phase III include, Alcon.
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Dry Eye Disease Report Insights
- Dry Eye Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Dry Eye Disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- Alcon
- HanAll Biopharma
- Ocular Therapeutix
- Seinda Pharmaceutical
- IVIEW Therapeutics
- Novaliq GmbH
- Kowa Company
- Seikagaku Corporation
- Aramis Biosciences
- Dreamhawk Vision Biotech, Inc.
- Taejoon Pharmaceutical
- Quorum Innovations
- Serentrix
- Noveome
- Allysta Pharmaceuticals
- BRIM Biotechnology
- Invirsa
Key Products
- AR-15512
- HL036
- OTX-DED
- SY-201
- iVIEW 1001
- CyclASol
- K-161
- SI-614
- A197
- SHJ 002
- TJO-083
- Qi 401
- SER-114
- ST-266
- ALY 688
- BRM421
- INV-102
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/cjpu5l
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
